<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FLUCONAZOLE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FLUCONAZOLE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#professionSpecificInformation" data-toggle="tab">Profession specific information</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Candidal balanitis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg for 1 dose.</li>
              <li class="dose child"><strong>For children 16&#8211;17 years</strong><br/>
                150 mg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Vaginal candidiasis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg for 1 dose.</li>
              <li class="dose child"><strong>For children 16&#8211;17 years</strong><br/>
                150 mg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Vulvovaginal candidiasis (recurrent)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 150 mg every 72 hours for 3 doses, then 150 mg once weekly for 6 months.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mucosal candidiasis (except genital)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg daily given for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14 days in atrophic oral candidiasis associated with dentures; for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections; increased to 100 mg daily, increased dose only for unusually difficult infections.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years</strong><br/>
                3&#8211;6 mg/kg, dose to be given on first day, then 3 mg/kg daily (max. per dose 100 mg) for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections).</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                50 mg for 7&#8211;14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14&#8211;30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100 mg daily, increased dose only for unusually difficult infections.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Tinea pedis, corporis, cruris, pityriasis versicolor</span>,
                <span class="indication">Dermal candidiasis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50 mg daily for 2&#8211;4 weeks (for up to 6 weeks in tinea pedis); max. duration of treatment 6 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Invasive candidal infections (including candidaemia and disseminated candidiasis) and cryptococcal infections (including meningitis)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg, dose to be given on first day, then 200&#8211;400 mg daily (max. per dose 800 mg daily) treatment continued according to response (at least 8 weeks for cryptococcal meningitis), maximum dose for use in severe infections.</li>
              <li class="dose child"><strong>For children </strong><br/>
                6&#8211;12 mg/kg daily (max. per dose 800 mg) treatment continued according to response (at least 8 weeks for cryptococcal meningitis).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of fungal infections in immunocompromised patients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                50&#8211;400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose adjusted according to risk.</li>
              <li class="dose child"><strong>For children </strong><br/>
                3&#8211;12 mg/kg daily (max. per dose 400 mg), commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose given according to extent and duration of neutropenia.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of fungal infections in immunocompromised patients (for patients with high risk of systemic infections e.g. following bone-marrow transplantation)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid&#8212;multiple congenital abnormalities reported with long-term high doses.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Toxicity with related drugs.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Usual initial dose then halve subsequent doses if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Usual initial dose then halve subsequent doses if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup> .</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal discomfort, diarrhoea, flatulence, headache, nausea, rash,
              </p>
              <p>
                <strong>uncommon:</strong> Alopecia, anaphylaxis, angioedema in children, dizziness, dyspepsia, hepatic disorders, hyperlipidaemia, hypersensitivity reactions in adults, pruritus, seizures, Stevens-Johnson syndrome, taste disturbance, toxic epidermal necrolysis, vomiting,
              </p>
              <p>
                <strong>notKnown:</strong> Hypokalaemia, leucopenia, thrombocytopenia,
              </p>
        
        
            <section class="advice">
              <p>If rash occurs, discontinue treatment (or monitor closely if infection invasive or systemic); severe cutaneous reactions are more likely in patients with AIDS.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, give over 10&#8211;30 minutes; do not exceed an infusion rate of 5&#8211;10&#8239;mL/minute.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Susceptibility to QT interval prolongation
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor liver function with high doses or extended courses&#8212;discontinue if signs or symptoms of hepatic disease (risk of hepatic necrosis).</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for tinea infections in children, or for vaginal candidiasis in girls under 16 years, or for prevention of relapse of cryptococcal meningitis after completion of primary therapy in children with AIDS.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Flavours of oral liquid formulations may include orange.</p>
            </section>
      </section>






      <section class="tab-pane" id="professionSpecificInformation">
        <h2>Profession specific information</h2>

          <h3>Dental practitioners</h3>
        
            <section class="dentalPractitionersFormulary">
              <p>Fluconazole Capsules 50&#8239;mg may be prescribed.</p><p>Fluconazole Oral Suspension 50&#8239;mg/5&#8239;mL may be prescribed.</p>
            </section>
      </section>

      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>Fluconazole capsules can be sold to the public for vaginal candidiasis and associated candidal balanitis in those aged 16&#8211;60 years, in a container or packaging containing not more than 150&#8239;mg and labelled to show a max. dose of 150&#8239;mg.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FLUCONAZOLE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP74600"><a href="../medicinalForm/PHP74600.html" data-target="#PHP74600" data-action="load">Capsule</a></div>
            <div id="PHP74594"><a href="../medicinalForm/PHP74594.html" data-target="#PHP74594" data-action="load">Oral suspension</a></div>
            <div id="PHP101318"><a href="../medicinalForm/PHP101318.html" data-target="#PHP101318" data-action="load">Infusion</a></div>
            <div id="PHP74617"><a href="../medicinalForm/PHP74617.html" data-target="#PHP74617" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
